Vol 58, No 1 (2024)
Response to Letter to the Editors
Published online: 2023-12-19

open access

Page views 261
Article views/downloads 213
Get Citation

Connect on Social Media

Connect on Social Media

Updates on pharmacological treatment for Alzheimer’s disease: response to Letter to the Editors

Philip W. Tipton1
Pubmed: 38112667
Neurol Neurochir Pol 2024;58(1):142-143.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Tipton PW. Updates on pharmacological treatment for Alzheimer's disease. Neurol Neurochir Pol. 2023 [Epub ahead of print].
  2. Gaggero G, Taietti D, Parrella V. Cerebral amyloid angiopathy associated with Alzheimer's disease: two pathologies from a single peptide? Neurol Neurochir Pol. 2023; [Epub ahead of print].
  3. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023; 388(1): 9–21.
  4. Sims JR, Zimmer JA, Evans CD, et al. TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330(6): 512–527.
  5. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023; 10(3): 362–377.
  6. Leurent C, Goodman JA, Zhang Y, et al. Ponezumab Trial Study Group. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy. Ann Clin Transl Neurol. 2019; 6(4): 795–806.



Neurologia i Neurochirurgia Polska